Earnings ·
Organogenesis Holdings Inc. reported second quarter 2026 financial results showing a sharp decline in performance
ORGOOrganogenesis Holdings Inc.
Organogenesis Holdings Inc. reported second quarter 2026 financial results showing a sharp decline in performance. Net revenue fell 58% to $42.8 million from $100.8 million in the prior year period, driven by a 61% drop in Advanced Wound Care sales to $36.1 million and an 18% decrease in Surgical & Sports Medicine revenue to $6.7 million. The company reported a net loss of $96.3 million, or $(0.77) per share, compared to a net loss of $9.4 million, or $(0.10) per share, in the second quarter of 2025. Adjusted EBITDA widened significantly to a loss of $34.4 million from a loss of $3.6 million year-over-year. Management updated its full-year 2026 revenue guidance downward to between $179.0 million and $215.0 million, reflecting slower-than-expected recovery from market contraction. As of June 30, 2026, the company held $46.8 million in cash and had no outstanding debt. Organogenesis Holdings Inc. operates in the regenerative medicine industry, developing and selling product solutions for Advanced Wound Care and Surgical & Sports Medicine markets.